PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 360271

Oncologic research and computerized data retrieval.

A B Karim·A Hasman·S C Chang
View original source ↗Export metadata ↓

Abstract

A computer-based data retrieval system for clinical research in oncology is described. The system has been designed to enable busy clinicians to retrieve and analyze data directly without major involvement of a computer specialist. The system uses texts similar to those in daily practice. In most situations no code is printed. The other important feature of the system is its ability to analyze clinical data in the form of tables, frequency distribution, etc. It may also furnish actuarial characteristics of the total population or subpopulations. Mathematical functions are calculated easily. Amendments and updating are simple enabling follow-up data to be incorporated. The system is under use for about 2 years and appears to be a versatile tool in the field of clinical research.

Explore related subjects

Clinical Trials as TopicComputersFemaleFollow-Up StudiesHumansLaryngeal NeoplasmsMaleMedical OncologyResearch DesignClinical TrialJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A B Karim, A Hasman, S C Chang. 1978. Oncologic research and computerized data retrieval.. https://pubmed.ncbi.nlm.nih.gov/360271/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer.

Difluoromethylornithine (DFMO) is a promising chemopreventive agent which is excreted unchanged in the urine, is active in vivo against superficial bladder cancer in animal tumor model systems, and has cytotoxic activity in vitro against superficial bladder cancer cells. Thus, DFMO may be particularly efficacious in preventing the development of bladder tumors and/or for the therapy of established superficial bladder cancer. To examine this hypothesis, an intergroup clinical trial is currently accruing patients with cystoscopically resected superficial bladder cancer (who would otherwise simply be observed). While the primary goal of this protocol is to define a daily dose of DFMO having little or no toxicity for use in future randomized chemoprevention trials, the rate of recurrent bladder tumors will also be followed in the hope that DFMO will inhibit the development of recurrent bladder cancers.

Clinical Trials as Topic↗